PharmaCyte Biotech, Inc.PMCBNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank82
Year-over-Year Change
Year-over-year operating cash flow growth rate
Latest
50.88%
↑ 279% vs avg
Percentile
P82
Within normal range
Streak
2 qtr
Consecutive growthAccelerating
Average
-28.44%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 50.88% |
| Q3 2025 | -91.66% |
| Q2 2025 | -104.04% |
| Q1 2025 | 51.66% |
| Q4 2024 | -182.55% |
| Q3 2024 | -12.12% |
| Q2 2024 | -88.00% |
| Q1 2024 | 91.07% |
| Q4 2023 | -678.60% |
| Q3 2023 | 218.92% |
| Q2 2023 | 46.76% |
| Q1 2023 | 71.17% |
| Q4 2022 | -73.30% |
| Q3 2022 | 9.02% |
| Q2 2022 | -299.08% |
| Q1 2022 | 78.45% |
| Q4 2021 | -11.63% |
| Q3 2021 | -32.00% |
| Q2 2021 | -59.61% |
| Q1 2021 | 52.89% |
| Q4 2020 | -126.94% |
| Q3 2020 | 13.82% |
| Q2 2020 | -81.53% |
| Q1 2020 | 39.65% |
| Q4 2019 | 23.52% |
| Q3 2019 | -15.39% |
| Q2 2019 | 2.24% |
| Q1 2019 | 26.29% |
| Q4 2018 | -47.50% |
| Q3 2018 | 54.73% |
| Q2 2018 | -17.21% |
| Q1 2018 | 26.54% |
| Q4 2017 | -70.64% |
| Q3 2017 | -16.82% |
| Q2 2017 | 13.45% |
| Q1 2017 | -31.00% |
| Q4 2016 | 22.12% |
| Q3 2016 | 25.58% |
| Q2 2016 | -20.50% |
| Q1 2016 | 3.94% |